42/100

Emerging evidence

Cite
More
EmailLinkedInX

Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI

Evidence type
News report
Sources
1 sourceJournalism
Published
1 min read

Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline. Under the agreement, Profluent will apply its foundational...

Profluent And BioMarin Pharmaceutical Inc. Partner To Design Novel Medicines Using AI

The gain

Profluent will use its AI platform to design and optimize novel enzyme therapies for BioMarin's drug pipeline under a new collaboration.

In brief

Profluent announced a collaboration with BioMarin Pharmaceutical Inc. to design and optimize novel enzyme therapies for BioMarin's pipeline, with Profluent applying its foundational technology under the agreement.

Main points

  1. Profluent announced a collaboration with BioMarin Pharmaceutical Inc.
  2. The stated goal is to design and optimize novel enzyme therapies for BioMarin's pipeline.
  3. Under the agreement Profluent will apply its foundational AI technology to the effort.

The full story

On September 30, 2026, Profluent announced a collaboration with BioMarin Pharmaceutical Inc. focused on novel enzyme therapies.

The agreement positions Profluent to apply its foundational platform to design and optimization work intended to support BioMarin's pipeline.

Sources

1 on file
  1. MarketScreenermarketscreener.com
    Journalism2026-09-30

Talk it over

What readers make of this record

What readers say